MOTS-c
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a mitochondrial-derived peptide — a short chain of amino acids encoded within mitochondrial DNA rather than the cell nucleus. It’s most often discussed in the context of metabolism and aging, where it’s studied as a signal the mitochondria appear to use to communicate with the rest of the cell.
Most of the evidence to date comes from cell and animal models. Human clinical data is limited and largely observational, and MOTS-c is not approved by any major regulator for therapeutic use. It is frequently grouped with other longevity- and metabolism-focused research peptides.
How it works
In preclinical studies, MOTS-c has been reported to influence energy-sensing pathways in the cell, including activation of AMPK — a regulator of how cells produce and use energy. Through these pathways, researchers have observed effects on glucose uptake and fat metabolism, primarily in skeletal muscle.
Levels of MOTS-c also appear to rise with exercise in animal and human observational studies, which has led some researchers to describe it as an exercise-responsive signal. The precise mechanism in humans is not established.
Reported benefits
- Improved glucose metabolism and insulin sensitivity (animal data)
- Support for fat metabolism and reduced weight gain in diet-induced obesity models (animal data)
- Improved exercise capacity and physical performance in aged animals
- Interest as a potential regulator of age-related metabolic decline
These are reported findings from preclinical research, not guaranteed outcomes in humans.
Considerations & side effects
Because rigorous human trials are lacking, the safety profile of MOTS-c in people is not well characterized, and long-term effects are unknown. General injectable-peptide considerations such as injection-site irritation may apply.
Product purity varies widely in the research-chemical market. MOTS-c is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is MOTS-c?
A small peptide encoded within mitochondrial DNA (the 12S rRNA region), studied largely in animal models for its effects on metabolism, exercise capacity, and aging.
Is MOTS-c FDA-approved?
No. MOTS-c is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
What is MOTS-c being studied for?
Preclinical research has explored its role in glucose and fat metabolism, insulin sensitivity, physical performance, and age-related metabolic decline.
Is MOTS-c the same as an exercise mimetic?
It is sometimes described that way because levels rise with exercise and, in animal studies, it produced adaptations resembling physical activity. This characterization comes from preclinical research, not established human therapy.
Is there strong human evidence for MOTS-c?
Human data is limited and largely observational. Most mechanistic and outcome evidence comes from cell and animal studies.
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. ↗
- Lee C, et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. ↗
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. ↗
- Kim SJ, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. ↗
Related compounds
Nicotinamide adenine dinucleotide. Essential coenzyme for cellular energy production and DNA repair. Levels decline with age. Administered via injection to bypass digestive breakdown.
First mitochondria-derived peptide discovered, encoded from mitochondrial DNA. Demonstrates cytoprotective and anti-apoptotic properties with particular relevance for neurological health and longevity.
Mitochondria-targeted tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane. Reduces oxidative stress and supports cellular energy production.